[Tafasitamab (diffuse large cell B-cell lymphoma, combination with lenalidomide) - Assessment according to § 35a (1), Sentence 11, Social Code Book V]
Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018004019
German
Original Title:
Tafasitamab (diffuses gro?zelliges B-Zell-Lymphom)
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/g21-26.html
Year Published:
2021
URL for published report:
https://www.iqwig.de/download/g21-26_tafasitamab_bewertung-35a-absatz-1-satz-11-sgb-v_v1-0.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Lymphoma, Large B-Cell, Diffuse
- Antibodies, Monoclonal, Humanized
- Lenalidomide
- Antineoplastic Combined Chemotherapy Protocols
Keywords
- Tafasitamab
- Lymphoma - Large B-Cell - Diffuse
- Health Care Costs
- Epidemiology
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.